Formulation and Evaluation of RSM Based Floating Alginate Microspheres of Gymnemic Acid & In Vitro-In Vivo Correlation (IVIVC) for Treatment of Diabetes Mellitus

Diabetes mellitus is a disease that is characterized by the chronic presence of blood glucose levels caused by a defect in the secretion of insulin or in the action of this hormone in the body which must be treated integrally with a multidisciplinary approach. The natural treatment of this disease is a common practice around the world, especially in Latin America, there are several clinical studies, in vivo or in vitro assays that focus on assessing the hypoglycemic capacity of various natural products used empirically by the population for years for the phytotherapeutic treatment of the disease as well as the chemicals related to the mechanism of action that produces the hypoglycaemic effect. In the present article, a brief review of the evidence of the hypoglycemic capacity of some natural products for the alternative treatment of diabetes mellitus 2

Download Full-text

The Effect of Momordica charantia in the Treatment of Diabetes Mellitus: A Review

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/3796265 ◽

2021 ◽

Vol 2021 ◽

pp. 1-14

Author(s):

Zhuo Liu ◽

Jing Gong ◽

Wenya Huang ◽

Fuer Lu ◽

Hui Dong

Keyword(s):

Diabetes Mellitus ◽

Clinical Trials ◽

Theoretical Basis ◽

Momordica Charantia ◽

In Vivo Experiments ◽

New Ideas ◽

Treatment Of Diabetes ◽

The Common

In recent years, many studies of Momordica charantia (MC) in the treatment of diabetes mellitus (DM) and its complications have been reported. This article reviewed the effect and mechanism of MC against diabetes, including the results from in vitro and in vivo experiments and clinical trials. The common side effects of MC were also summarized. We hope that it might open up new ideas for further mechanism exploration and clinical application as well as provide a scientific theoretical basis for the development of drugs or foods derived from MC.

Download Full-text

Hybrid drug combination: A new treatment strategy for type 2 diabetes- A review

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v11i2.2131 ◽

2020 ◽

Vol 11 (2) ◽

pp. 2008-2017

Author(s):

Shraddha Sharma ◽

Vengal Rao P ◽

Seema Mehdi ◽

Manjula S N ◽

Aalap Das

Keyword(s):

Diabetes Mellitus ◽

Side Effects ◽

Synthetic Drugs ◽

Treatment Of Diabetes ◽

New Treatment ◽

Bioactive Agents ◽

Oral Hypoglycemic Drugs

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia arising from deregulation in insulin secretion, insulin action, or both. The current synthetic drugs have dose-dependent side effects which confined their uses. The phytochemicals are the natural compounds that have better therapeutic efficacy and interacts synergistically with oral hypoglycemic drugs. The addition of phytochemicals with OHDs may reduce the dose of synthetic drugs as well as their side effects and toxicity. A detailed outline about such combinations like Ferulic acid & THZ/Metformin, Ellagic acid & Pioglitazone (THZ), Chlorogenic acid & THZ/Metformin, Caffeic acid & THZ/Metformin, eugenol acid & THZ/Metformin, cinnamic acid & THZ/Metformin, p- coumaric acid & THZ/Metformin, Arecoline &Vanillic acid with the THZ/ Metformin have been illustrated. This review has also discussed the synergy and mechanism of phytochemical with the OHDs to combat hyperglycemia and other risk associated with it. A comprehensive review was conducted to pile up the information about polyphenols & synthetic drug combinations used for the treatment of diabetes mellitus, which has been carried out in-vitro or in-vivo and may contribute to identifying novel strategies in the treatment of T2D condition. This review shows the importance of the responsible bioactive agents present in medicinal plants in the drive to demonstrate their antidiabetic effects.

Download Full-text

Preventive and Protective Properties ofZingiber officinale(Ginger) in Diabetes Mellitus, Diabetic Complications, and Associated Lipid and Other Metabolic Disorders: A Brief Review

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2012/516870 ◽

2012 ◽

Vol 2012 ◽

pp. 1-10 ◽

Cited By ~ 38

Author(s):

Yiming Li ◽

Van H. Tran ◽

Colin C. Duke ◽

Basil D. Roufogalis

Keyword(s):

Diabetes Mellitus ◽

Zingiber Officinale ◽

Neural System ◽

Protective Effects ◽

Protective Properties ◽

Safety Issues ◽

Carbohydrate And Lipid Metabolism ◽

Treatment Of Diabetes

Zingiber officinale(ginger) has been used as herbal medicine to treat various ailments worldwide since antiquity. Recent evidence revealed the potential of ginger for treatment of diabetes mellitus. Data fromin vitro, in vivo, and clinical trials has demonstrated the antihyperglycaemic effect of ginger. The mechanisms underlying these actions are associated with insulin release and action, and improved carbohydrate and lipid metabolism. The most active ingredients in ginger are the pungent principles, gingerols, and shogaol. Ginger has shown prominent protective effects on diabetic liver, kidney, eye, and neural system complications. The pharmacokinetics, bioavailability, and the safety issues of ginger are also discussed in this update.

Download Full-text

Extrinsic Factors Involved in the Differentiation of Stem Cells into Insulin-Producing Cells: An Overview

Experimental Diabetes Research ◽

10.1155/2011/406182 ◽

2011 ◽

Vol 2011 ◽

pp. 1-15 ◽

Cited By ~ 21

Author(s):

Rebecca S. Y. Wong

Keyword(s):

Diabetes Mellitus ◽

Stem Cells ◽

Human Subjects ◽

Contributing Factors ◽

Extrinsic Factors ◽

Oral Hypoglycaemic Agents ◽

Insulin Producing Cells ◽

Treatment Of Diabetes

Diabetes mellitus is a chronic disease with many debilitating complications. Treatment of diabetes mellitus mainly revolves around conventional oral hypoglycaemic agents and insulin replacement therapy. Recently, scientists have turned their attention to the generation of insulin-producing cells (IPCs) from stem cells of various sources. To date, many types of stem cells of human and animal origins have been successfully turned into IPCsin vitroand have been shown to exert glucose-lowering effectin vivo. However, scientists are still faced with the challenge of producing a sufficient number of IPCs that can in turn produce sufficient insulin for clinical use. A careful choice of stem cells, methods, and extrinsic factors for induction may all be contributing factors to successful production of functional beta-islet like IPCs. It is also important that the mechanism of differentiation and mechanism by which IPCs correct hyperglycaemia are carefully studied before they are used in human subjects.

Download Full-text

TRIGONELLA FOENUM : A REVIEW OF HYPOGLYCEMIC ACTIVITY

Jurnal Natural ◽

10.24815/jn.v19i3.13405 ◽

2019 ◽

Vol 19 (3) ◽

pp. 72-76

Author(s):

Suryawati Suryawati ◽

Safrida Safrida ◽

Firdausa Sarah ◽

Azizah Vonna ◽

Vera Dewi Mulia

Keyword(s):

Diabetes Mellitus ◽

Heart Disease ◽

Folk Medicine ◽

Hypoglycemic Agents ◽

Glucose Regulation ◽

Converting Enzyme ◽

Trigonella Foenum Graecum ◽

Treatment Of Diabetes

Treatment of diabetes mellitus is intended to reduce the risk of blindness, kidney failure, neuropathy and heart disease that can develop due to the chronic increase in the blood glucose level. The selected hypoglycemic agents should be effective, safe and readily available. The widely used agents work by interrupting enzymes responsible for glucose regulation. Those enzymes are α-amilase, α-glucosidase, dipeptidyl peptidase-IV, aldose reductase and angiotensin converting enzyme. A medicinal plant, fenugreek (Trigonella foenum-graecum) has been used as an antidiabetic folk medicine. This review provides information related to in vitro studies showing antihyperglycemic activity of fenugreek along with an in vivo study in animals. In addition, potential phytochemicals that have been isolated from this plant are described and play a role in the searching for the most potent agents for diabetes mellitus therapy.

Download Full-text

Gymnemic Acid Alleviates Type 2 Diabetes Mellitus and Suppresses Endoplasmic Reticulum Stress in Vivo and in Vitro

Journal of Agricultural and Food Chemistry ◽

10.1021/acs.jafc.9b00431 ◽

2019 ◽

Vol 67 (13) ◽

pp. 3662-3669 ◽

Cited By ~ 9

Author(s):

Yumeng Li ◽

Mingzhe Sun ◽

Yaping Liu ◽

Junjie Liang ◽

Tianxin Wang ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Endoplasmic Reticulum ◽

Type 2 Diabetes Mellitus ◽

Endoplasmic Reticulum Stress ◽

Gymnemic Acid

Download Full-text

Development and Characterization of Pioglitazone Nanoparticles for the Effective Treatment of Diabetes Mellitus

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2021/v33i31a31678 ◽

2021 ◽

pp. 172-182

Author(s):

Revathi A. Gupta ◽

P. Odaya Kumar

Keyword(s):

Diabetes Mellitus ◽

Drug Release ◽

Average Particle Size ◽

Tween 80 ◽

Cubic Phase ◽

Average Particle ◽

Drug Release Profile ◽

Treatment Of Diabetes

Pioglitazone is designated as a BCS class II medication since it is weakly water soluble.The goal of this study was to create starch nanoparticles for the administration of Pioglitazone in attempt to lessen dose-related side effects and maybe prolong its release in the treatment of diabetes.Using starch as a polymer, tween 80 as a stearic barrier, and citric acid to enhance stability, nanoparticles were constructed using the solvent evaporation technique. In-vitro characterization techniques for drug-polymer compatibility, size, surface morphology, encapsulation efficacy, and delivery properties were performed on framed nanoparticles, followed by In-vivo studies.The compatible nature of selected excipients for the manufacture of Pioglitazone nanoparticles was shown by FTIR findings.The results of the XRD analysis revealed that the generated Pioglitazone nanoparticles were non-crystalline in nature.The selected developed Pioglitazone nanoparticles were in cubic phase with average particle size of 160.5 ± 11.24–245.4 ± 15.96 nm with charge ranging from 10.5 ± 6.21-138.6 ± 5.31mV.The encapsulation efficiency of Pioglitazone nanoparticles produced ranged from 57.24 5.80 to 89.96 1.9%. The In-vitro drug release studies of Pioglitazone nanoparticles showed controlled drug release profile. Furthermore, In-vivo investigations on blood glucose profiles revealed that the created Pioglitazone nanoparticles for the treatment of diabetes mellitus had a substantial effect.

Download Full-text